IN THE CLAIMS

1. - 13. (cancelled)

14. (original) A pharmaceutical composition comprising an inhibitor of S-adenosyl methionine decarboxylase and another agent efficient against a herpes simplex virus infection, in a pharmaceutically acceptable carrier.

15. (currently amended) The pharmaceutical composition ~~according to~~ of claim 14, wherein said agent is acyclovir.

16. (currently amended) The pharmaceutical composition ~~according to~~ of claim 14 ~~or 15~~, wherein said inhibitor is SAM486A.

17. (new) The pharmaceutical composition of claim 15, wherein said inhibitor is SAM486A.

18. (new) A method for preventing or treating a herpes simplex virus infection, comprising administering an effective amount of a medicament comprising an inhibitor of S-adenosyl methionine decarboxylase (SAMDC).

19. (new) The method of claim 18, wherein said herpes simplex virus is HSV-1 or HSV-2.

20. (new) The method of claim 18, wherein said inhibitor is administered in association with another agent efficient against a herpes simplex virus infection.

21. (new) The method of claim 19, wherein said inhibitor is administered in association with another agent efficient against a herpes simplex virus infection.

22. (new) The method of claim 20, wherein said agent is acyclovir.

23. (new) The method of claim 21, wherein said agent is acyclovir.

24. (new) The method of claim 18, wherein said herpes simplex virus is a HSV-1 strain resistant to acyclovir, foscarnet, and/or their derivatives.

25. (new) The method of claim 20, wherein said herpes simplex virus is a HSV-1 strain resistant to acyclovir, foscarnet, and/or their derivatives.

26. (new) The method of claim 18, wherein said medicament is administered to a human.

27. (new) The method of claim 19, wherein said medicament is administered to a human.

28. (new) The method of claim 20, wherein said medicament is administered to a human.

29. (new) The method of claim 18, wherein said medicament is administered to a non-human mammal.

30. (new) The method of claim 19, wherein said medicament is administered to a non-human mammal.

31. (new) The method of claim 20, wherein said medicament is administered to a non-human mammal.

32. (new) The method of claim 26, wherein said human is an immunodepressed subject.

33. (new) The method of claim 27, wherein said human is an immunodepressed subject.

34. (new) The method of claim 28, wherein said human is an immunodepressed subject.

35. (new) The method of claim 18, wherein said inhibitor is SAM486A.

36. (new) The method of claim 18, wherein said inhibitor is an inhibitor of SAMDC expression.

37. (new) The method of claim 18, wherein said inhibitor is an antisense nucleic acid sequence that blocks expression of SAMDC.

38. (new) The method of claim 18, wherein said inhibitor inhibits the replication of HSV in cellulo.